Ray’s Fav Recco

Posted On Sep 24, 2021 By Addison Wiggin

Meet a company that has set its sights on fighting inflammation — which is essentially what happens when your immune system is triggered. As we get older, our immune systems can keep reacting as if the body is under attack. The constant state of inflammation may lead to autoimmune diseases like rheumatoid arthritis, as well as various types of cancer. One of the key chemicals responsible for the immune system’s overreaction is called TNF alpha. And scientists discovered a chemical in tobacco that could be modified to inhibit the production of TNF alpha. The first drug to use this chemical was approved in 2002. “It was the first antibody therapeutic approved by the FDA,” Ray says. And today, “the best selling, most successful drugs in history are TNF alpha blockers.” You may have heard of them, including AbbVie’s Humira and Amgen’s Enbrel. All told, they’re a $40 billion market. But there’s a small problem…

Subscribe to Platinum Reserve Today!

From blue chips to penny stocks, income plays to growth opportunities, commodities to techs, ETFs to OTCs, bonds to options — the Agora Financial Platinum Reserve covers it all. You simply cannot find a more comprehensive source of investment analysis and recommendations.

Subscribe Today!